Advancing Therapies for Patients

Find a clinical trial

page image

Open Clinical Trials

shadow image

Text Size

minus image

plus image

plus image

Print

Print image

Email a Friend

You are here: SCRI-UK

/Open Clinical Trials

Find a clinical trial

Open Clinical Trials

All of our clinical trials are listed on this page.  Click the arrow button on the right to see more details about that trial on ClinicalTrials.gov, a database of publicly and privately supported clinical trials around the world.

If you are a patient interested in taking part in a clinical trial, please speak to your doctor or cancer specialist.  If you are a doctor and have a patient you believe may be eligible for an ongoing clinical trial, please do not hesitate to contact us, or click here to access the Sarah Cannon Research Institute UK Patient Referral document.

Open and Recruiting

View all trials

 

Phase I

ATR protein kinase inhibitor

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803 as a Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors or Lymphoma (REFMAL 385)

Adjuvant PD-L1

A Study comparing the efficacy and safety of atezolizumab (MPDL3280A) versus observation in participants with bladder cancer with risk features for recurrence after cystectomy (GU 125)

 

Diffuse Large B-cell Lymphoma

anti PD-L1 inhibitor

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (LYM112)

Glycoengineered antibody

A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA (LYM 113)

 

Gastric

Monoclonal Antibody

A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) (GI 230)

MGC

RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC GASTRIC CANCER REFRACTORY TO STANDARD TREATMENTS (GI 229)

 

Prostate

Anti-PD-L1 Antibody

A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN (GU 139)

Parp inhibitor

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (GU 142)

Parp inhibitor

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (GU 146)

 

Breast

Tyrosine kinase inhibitor vs anti-HER2 antibody

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (BRE 271)

CDK4/6 inhibitor

Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in
Combination with Fulvestrant in Patients with Hormone Receptor-Positive,
HER2-Negative Locally Advanced or Metastatic Breast Cancer after Endocrine Failure (BRE 282)

ATP-competitive inhibitor of CD K4 and CDK6

A Randomized, Open-Label, Phase 3 Study of Abemaciclib
Combined with Standard Adjuvant Endocrine Therapy versus
Standard Adjuvant Endocrine Therapy Alone in Patients with
High Risk, Node Positive, Early Stage, Hormone Receptor
Positive, Human Epidermal Receptor 2 Negative, Breast
Cancer (BRE 296)

 

Ovarian

WEE1 kinase inhibitor

A Multicentre Phase II Study of AZD1775 plus Chemotherapy in Patients
with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary
Peritoneal Cancer (GYN49)

 

Lung

cMet RTK inhibitor

A phase II, multicentre, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease (LUN 306)

Potential CYP2C8 and CYP3A4 inhibitor

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial) (LUN 337)

 

Bladder

anti PD-L1 inhibitor

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY) (GU 118)

 

Multiple Myeloma

FGFR inhibitor

An open-label, Dose-escalation and Dose-expansion, Phase I/ II Study of TAS-120, Evaluating the Safety, Tolerability, PK, Pharmacodynamic, and Antitumor Activity of TAS-120 in Patients with Advanced Solid Tumors or Multiple myeloma with and without FGF/FGFR-related abnormalities (REFMAL 340)

 

Pancreas

Recombinant human PH20 hyaluronidase enzyme conjugated to polyethylene glycol (PEG)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma [GI 232]

 

Solid Tumours

Anti-PD-1 Monoclonal Antibody

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors (MULTI-14)

FGFR, VEGFR, RET inhibitor

Safety and tolerability of single and repeated doses of ODM-203: an open-label, non-randomised, uncontrolled, dose escalation, multicentre, first in-human study in subjects with advanced solid tumours (REFMAL 469)

HSP90 inhibitor

A Phase IA/IB Study evaluating TAS-116 in Patients with Advanced Solid Tumors (REFMAL 499)

Bruton's tyrosine kinase (Btk) inhibitor

Phase 1b/2 study in multiple gastrointestinal and genitourinary solid tumours [MULTI 08]

Tyrosine kinase inhibitor

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements [MULTI 05]

Anti PD-L1A

A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancers (REFMAL 459)

PD L1 ProbodyTM therapeutic

An Open Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic, CX-072, as Monotherapy and in Combination with Yervoy® (Ipilimumab) or with Zelboraf® (Vemurafenib) in Subjects with Advanced or Recurrent Solid Tumours or Lymphomas (REFMAL 477)

cMET Inhibitor

A multicenter, open label, phase 1 dose escalation study to
evaluate the pharmacokinetics, safety, and tolerability of
INC280 tablet formulation with food in patients with cMET
dysregulated advanced solid tumors (REFMAL 493)

Please also visit www.clinicaltrials.gov. Click here to access the SCRUK Patient Referral document.

Latest Videos

watch the latest videos.

Learn more

News

news from the industry.

Read more

hero1 image
Sarah Cannon Research UK NHS Ventures
University College London Hospitals
LOC